The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Open accessAbstract
Proteasomes are large, multisubunit proteolytic complexes presenting multiple targets for therapeutic intervention. The 26S proteasome consists of a 20S proteolytic core and one or two 19S regulatory particles. The 20S core contains three types of active sites. Many structurally diverse inhibitors of these active sites, both natural product and synthetic, have been discovered in the last two decades. One, bortezomib, is used clinically for treatment of multiple myeloma, mantle cell lymphoma, and acute allograft rejection. Five more recently developed proteasome inhibitors are in trials for treatment of myeloma and other cancers. Proteasome inhibitors also have activity in animal models of autoimmune and inflammatory diseases, reperfusion injury, promote bone and hair growth, and can potentially be used as anti-infectives. In addition, inhibitors of ATPases and deubiquitinases of 19S regulatory particles have been discovered in the last decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Activators and Target Genes of Rel/NF-кB Transcription Factors: From Bench to Bedside
Loop, T., & Pahl, H. L. (2003) · Nuclear Factor кB · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,169
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES
Coux, O., Tanaka, K., & Goldberg, A. L. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.004101 · Cited by 2,487
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
Finley, D. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081507.101607 · Cited by 1,764
Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583
Cited by
Targeting the unfolded protein response in disease
Hetz, C., Chevet, E., & Harding, H. P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3976 · Cited by 910
Emerging Targets in Photopharmacology
Lerch, M. M., Hansen, M. J., van Dam, G. M., Szymanski, W., & Feringa, B. L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601931 · Cited by 675
Mitochondrial metabolism promotes adaptation to proteotoxic stress
Tsvetkov, P., Detappe, A., Cai, K., Keys, H. R., Brune, Z., Ying, W., Thiru, P., Reidy, M., Kugener, G., Rossen, J., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0291-9 · Cited by 645
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
Zolotovskaia, M. A., Sorokin, M. I., Emelianova, A. A., Borisov, N. M., Kuzmin, D. V., Borger, P., Garazha, A. V., & Buzdin, A. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00001 · Cited by 531
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Churcher, I. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01272 · Cited by 491
MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
Winters, A. C., & Bernt, K. M. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00004 · Cited by 405
Li, C., Wang, J., Barton, L. M., Yu, S., Tian, M., Peters, D. S., Kumar, M., Yu, A. W., Johnson, K. A., Chatterjee, A. K., et al. (2017) · Science · doi:10.1126/science.aam7355 · Cited by 379
ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors
Halasi, M., Wang, M., Chavan, T. S., Gaponenko, V., Hay, N., & Gartel, A. L. (2013) · Biochemical Journal · doi:10.1042/bj20130282 · Cited by 366
Redox Signaling by Reactive Electrophiles and Oxidants
Parvez, S., Long, M. J. C., Poganik, J. R., & Aye, Y. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00698 · Cited by 359
A Practical Review of Proteasome Pharmacology
Thibaudeau, T. A., & Smith, D. M. (2019) · Pharmacological Reviews · doi:10.1124/pr.117.015370 · Cited by 344
Selective Autophagy of BES1 Mediated by DSK2 Balances Plant Growth and Survival
Nolan, T. M., Brennan, B., Yang, M., Chen, J., Zhang, M., Li, Z., Wang, X., Bassham, D. C., Walley, J., & Yin, Y. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.03.013 · Cited by 339
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Development of proteasome inhibitors as research tools and cancer drugs
Goldberg, A. L. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201210077 · Cited by 291
Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Wang, W., Nag, S., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106124315 · Cited by 282
Dou, Q., & Zonder, J. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140804154511 · Cited by 275
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Xie, Z., Nolan, T., Jiang, H., Tang, B., Zhang, M., Li, Z., & Yin, Y. (2019) · The Plant Cell · doi:10.1105/tpc.18.00918 · Cited by 265
Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation
Zhang, T., Hatcher, J. M., Teng, M., Gray, N. S., & Kostic, M. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.09.012 · Cited by 178
Ramachandran, K. V., & Margolis, S. S. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3389 · Cited by 151
The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target
Cromm, P. M., & Crews, C. M. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00252 · Cited by 136
Privileged Electrophile Sensors: A Resource for Covalent Drug Development
Long, M. J. C., & Aye, Y. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.023 · Cited by 81
Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome
Tsvetkov, P., Mendillo, M. L., Zhao, J., Carette, J. E., Merrill, P. H., Cikes, D., Varadarajan, M., van Diemen, F. R., Penninger, J. M., Goldberg, A. L., et al. (2015) · eLife · doi:10.7554/elife.08467 · Cited by 83
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Ebstein, F., Küry, S., Most, V., Rosenfelt, C., Scott-Boyer, M.-P., van Woerden, G. M., Besnard, T., Papendorf, J. J., Studencka-Turski, M., Wang, T., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3189 · Cited by 36
Gomez, A. R., Byun, H. R., Wu, S., Muhammad, A. K. M. G., Ikbariyeh, J., Chen, J., Muro, A., Li, L., Bernstein, K. E., Ainsworth, R., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00879-1 · Cited by 13
Metadata
- Authors
- Kisselev, A. F., van der Linden, W. A., & Overkleeft, H. S.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 19
- Issue
- 1
- Pages
- 99-115
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W1999042605
- Cited by
- 527
- References
- 132
- FWCI
- 22.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.